FindTrial
Sign In

A real-world study of oral Baritinib (Alemin) in the treatment of alopecia areata

A real-world study of oral Baritinib (Alemin) in the treatment of alopecia areata

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040700
Enrollment
Unknown
Registered
2020-12-08
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

alopecia areata

Interventions

alopecia areata:Baricitinib

Sponsors

Shanghai Skin Disease Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: All patients with alopecia areata treated clinically with Baritinib.

Exclusion criteria

Exclusion criteria: 1. Despite the clinical application of Baritinib, the patients were unwilling to sign the informed consent and did not agree to follow up; 2. Other conditions not considered suitable for inclusion by the researchers.

Design outcomes

Primary

MeasureTime frame
SALT;—

Countries

China

Contacts

Public ContactJing Zhou

Shanghai Skin Disease Hospital

vine_vs_vine@126.com+86 18017336871

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026